MTAP and colorectal carcinoma: MTAP-loss tumors had a lower prevalence of concomitant MSI-H in CRC (0.5% vs 5.7%, P < .0001), IHCC (0.4% vs 2.1%, P = .001), and PDAC (0.1% vs 0.6%, P = .0008; Fig. 4A).